Abstract
BACKGROUND:
Endocrinopathy, including hypogonadism, is common following traumatic brain injury (TBI). Prior evidence suggests hypogonadism is associated with poorer function.
OBJECTIVE:
Determine the feasibility, safety, and efficacy of testosterone (T) therapy in hypogonadal men following TBI in acute rehabilitation.
DESIGN:
Randomized, double blind, placebo-controlled pilot trial.
SETTING:
Inpatient rehabilitation brain injury unit.
PARTICIPANTS:
Men ages 18 –65, post moderate to severe TBI receiving inpatient rehabilitation.
INTERVENTIONS:
Transdermal T gel or placebo.
MAIN OUTCOME MEASURES:
Revised FIM™ score, strength, adverse events.
RESULTS:
Of 498 screened, 70 participants were enrolled, and 22 meeting all criteria were randomized into placebo (n = 10) or physiologic T therapy (n = 12). There was no significant difference between groups in rate of improvement on the FIM™ (intercepts t = –0.31, p = 0.7593, or slopes t = 0.61, p = 0.5472). The Treatment group demonstrated the greatest absolute improvement in FIM™ scores and grip strength compared to Placebo or Normal T groups. There was no difference in adverse events between groups. Percentage of time with agitation or aggression was highest in the Placebo group.
CONCLUSIONS:
Although there were no significant differences in rates of recovery, treatment group subjects showed greater absolute functional and strength improvement compared to the Placebo or Normal T groups.
Keywords
Get full access to this article
View all access options for this article.
